cisplatin,gemcitabine,nivolumab
bms
['gu ', 'mibc', 'nivolumab', 'cisplatin', 'hcrn,gu,16-257', 'nivo', 'gemcitabine', 'bladder']
md. galsky talk about hcrn gu 16-257: phase 2 trial of gemcitabine, cisplatin + nivo with selective bladder sparing in pts with mibc. transurethral resection of bladder tumor followed by gem, cisp+nivo achieves stringently defined ccr in a subset of pts with mibc. #ascogu23 
Medical Oncologist at Centro Oncológico Integral, Hospital Ángeles Puebla. Cancer treatment must be personalized to the individual needs of the patient.